BridgeBio Q1 net loss narrows to $140M ($0.92 loss per share); cash $467M after $150M offering

BridgeBio Pharma, Inc.

2023-Q1 EPS reported -$0.92 revenue$1,826,000

Net loss attributable to common stockholders $140.2M ($0.92 diluted EPS) vs $196.4M ($1.35) in Q1 2022; revenue $1.8M flat.
Operating expenses fell 27% YoY to $128.0M from $175.4M, reflecting cost restructuring and program reprioritization.
Cash, equivalents, marketable securities, and restricted cash $467.0M; includes $143M net from follow-on offering closed in March 2023.
Phase 3 ATTR-CM trial of acoramidis completed last patient last visit; topline month-30 data expected late July 2023.
Infigratinib (achondroplasia) Phase 2 Cohort 5 showed +3.03 cm/yr annualized height velocity; 80% responders; Phase 3 run-in started.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.